The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program may run into problems with voluntary participation and expense concerns.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.